The Effects of Pegylated Interferon-Lambda Treatment on SARS-CoV-2-specific T Cell Responses
Year: 2022
Type: dissertation
Abstract: Interferon lambda (IFN-λ), a type III interferon, is a key component of the innate antiviral immune response. Type III IFNs use a receptor with limited expression to epithelial cells. However, it has recently been shown that specific immune cells, including T cells, express the receptor. We recently completed a randomized clinical trial using pegylated IFN-λ (PEG-IFN-λ) to treat mild-to-moderate COVID-19 and demonstrated accelerated viral clearance with treatment. Whether IFN-λ influences virus-specific T cell responses and whether this contributes to its antiviral activity are unknown. SARS-CoV-2-specific responses in PEG-IFN-λ trial patients towards the spike, nucleocapsid, and membrane proteins were measured in this study. PEG-IFN-λ did not affect the magnitude or breadth of SARS-CoV-2-specific T cells, however we identified a delay in T cell responses in older patients. Overall, our results demonstrate that the accelerated viral clearance observed in our clinical trial was not the result of an enhancement in SARS-CoV-2-specific T cell responses.
Source: TSpace (University of Toronto)
Author: Li, Daniel
Institution: University of Toronto
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7133013902
